PYC Historical Cash Flow
| PYC Stock | 1.28 0.07 5.19% |
Analysis of PYC Therapeutics cash flow over time is an excellent tool to project PYC Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 18.8 M or Depreciation of 1.3 M as it is a great indicator of PYC Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining PYC Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PYC Therapeutics is a good buy for the upcoming year.
PYC |
About PYC Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in PYC balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which PYC's non-liquid assets can be easily converted into cash.
PYC Therapeutics Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by PYC Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of PYC Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from PYC Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into PYC Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, PYC Therapeutics' Dividends Paid is comparatively stable compared to the past year.
| 2021 | 2024 | 2025 (projected) | Dividends Paid | 10.5M | 9.4M | 18.7M | Issuance Of Capital Stock | 12.7M | 105.9M | 111.2M |
PYC Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
PYC Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PYC Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 591.0K | 386.9K | 491.1K | 307.0K | 353.1K | 224.6K | |
| Total Cash From Operating Activities | (11.8M) | (21.8M) | (24.4M) | (38.6M) | (34.7M) | (33.0M) | |
| Total Cash From Financing Activities | 38.6M | (182.4K) | 11.4M | 90.2M | 103.7M | 108.9M | |
| End Period Cash Flow | 18.4M | 29.1M | 15.6M | 66.9M | 76.9M | 80.8M | |
| Sale Purchase Of Stock | (1.6M) | (2.3M) | (976.2K) | (1.6M) | (1.4M) | (1.3M) | |
| Change In Cash | 11.2M | 10.7M | (13.5M) | 51.3M | 59.0M | 61.9M | |
| Free Cash Flow | (12.4M) | (22.2M) | (24.9M) | (38.9M) | (35.0M) | (33.3M) | |
| Begin Period Cash Flow | 7.2M | 18.4M | 29.1M | 15.6M | 17.9M | 18.8M | |
| Other Cashflows From Financing Activities | (226.6K) | (182.4K) | (232.8K) | (294.5K) | (265.0K) | (278.3K) | |
| Depreciation | 622.4K | 839.5K | 882.0K | 1.1M | 1.2M | 1.3M | |
| Other Non Cash Items | 1.6M | 11.5M | 3.0M | 229.1K | 206.2K | 195.8K | |
| Net Income | (17.8M) | (13.9M) | (22.8M) | (37.7M) | (34.0M) | (32.3M) | |
| Change To Account Receivables | (133.3K) | (9.8M) | (6.2M) | (2.4M) | (2.2M) | (2.1M) | |
| Stock Based Compensation | 3.6M | 612.7K | (70.3K) | 247.4K | 284.5K | 270.3K | |
| Change In Working Capital | 2.6M | (8.9M) | (2.0M) | (2.2M) | (1.9M) | (1.8M) | |
| Total Cashflows From Investing Activities | (13.8M) | (15.5M) | 32.7M | (477.1K) | (548.7K) | (576.1K) | |
| Change To Operating Activities | 129.8K | 222.1K | 527.6K | (139.9K) | (160.9K) | (152.9K) | |
| Change To Netincome | 472.0K | 2.8M | 182.2K | (554.2K) | (637.4K) | (605.5K) | |
| Change To Liabilities | 21.0K | 2.5M | 262.3K | 4.3M | 5.0M | 5.2M | |
| Change To Inventory | 1.0 | (2.7M) | (892.8K) | (4.2M) | (3.8M) | (3.6M) | |
| Investments | (14.9M) | 33.1M | (477.1K) | (307.0K) | (353.1K) | (370.8K) | |
| Issuance Of Capital Stock | 26.9M | 41.1M | 12.7M | 92.1M | 105.9M | 111.2M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.